Zomedica Corp. Reports Record 2025 Financial Results
Zomedica Corp. (OTCQB: ZOMDF) announced on March 16, 2026 that it achieved record fourth‑quarter revenue of $10.5 million and total annual revenue of $32.0 million for the year ended December 31, 2025.
The company reported a 17 % year‑over‑year growth and a 68 % gross margin for the year. Operating cash and liquidity totaled $53.3 million at the end of 2025.
Key Highlights
| Metric | 2025 | 2024 | % Change |
|---|---|---|---|
| Revenue | $32.0 M | $26.7 M | +17 % |
| Gross Margin | 68 % | — | — |
| Liquidity | $53.3 M | — | — |
| Fourth‑quarter revenue | $10.5 M | $8.0 M | +31 % |
| Quarterly record | 20th straight quarter | — | — |
- The fourth‑quarter revenue milestone surpassed the company’s previous record of $8 million set in Q3 2025, marking the first time Zomedica has exceeded $10 million in a single quarter.
- The sustained revenue growth for the twentieth consecutive quarter demonstrates consistent demand for Zomedica’s portfolio of point‑of‑care diagnostic and therapeutic products for equine and companion animals.
- The company’s CEO, Larry Heaton, emphasized that the growth is driven by strong and sustained demand for PulseVet® and Assisi® therapeutic devices, as well as accelerating adoption of its diagnostic offerings.
Company Context
Zomedica Corp. is a veterinary biopharmaceutical company focused on drug discovery and development for pet health. Operating within the Health Care sector, the company serves North American veterinarians and customers. Its primary exchange is the OTC Bulletin Board, and its market capitalization as of March 15, 2026 is $123 million. The company’s share price closed at $0.1275 on that date, with a 52‑week high of $0.158 and a low of $0.035. The price‑earnings ratio is –1.477.
Zomedica’s product line includes the PulseVet® diagnostic device and the Assisi® therapeutic device, both of which have contributed significantly to the recent revenue expansion. The company maintains a liquidity cushion of $53.3 million, which supports ongoing R&D and commercialization activities.
The financial results were reported by ACCESS Newswire and corroborated by multiple financial data providers, including www.finanznachrichten.de , www.otcmarkets.com , and www.allpennystocks.com .
